New agents approved for treatment of acute staphylococcal skin infections

Tatarkiewicz, Jan; Staniszewska, Anna; Bujalska‐Zadrożny, Magdalena

doi:10.5114/aoms.2016.59838

Cited by 18 publications

(9 citation statements)

References 33 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tedizolid, a newer antibiotic agent of the oxazolidinone class for oral and intravenous administration, has similar indications. 20 Ceftaroline is a fifth-generation cephalosporine having activity against gram-positive bacteria, like MRSA, and some gram-negative pathogens and has also been approved for the treatment of acute bacterial skin and skin structure infections. 21…”

Section: Infectious Managementmentioning

confidence: 99%

A Peep in to Novel Therapies in Diabetic Foot Ulcer

Jasir¹,

Kameswaran²

2021

IJAR

View full text Add to dashboard Cite

Diabetic Foot Ulcer represent a complex entity resulting from several contributing pathways including neuropathy, vascular disease, and metabolic derangement, which may occur alone or in concert with each other. DFU affects patients physically, mentally and economically. Offloading, debridement, infectious controlling and revascularization remains as the mainstay in treatment of diabetic foot. Antibiotic resistance are also observed frequently in these patients. These current standard of treatment is still not showing much recovery in patients. In this era novel approaches to the treatment of DFU gain more interest. This review aims to summarize the novel approaches that are in practice for the diabetic foot ulcer treatment along with clinical evidences from the randomized control trials. Still many procedures lack much evidence and their efficacy and safety need to be determined.

show abstract

Section: Infectious Managementmentioning

confidence: 99%

A Peep in to Novel Therapies in Diabetic Foot Ulcer

Jasir¹,

Kameswaran²

2021

IJAR

View full text Add to dashboard Cite

show abstract

“…Staphylococcus aureus ( S. aureus ) is one of the most common causes of human diseases, ranging from skin and soft tissue infections to pneumonia, meningitis, and sepsis [ 1 ]. S. aureus infections and, specifically, methicillin-resistant S. aureus (MRSA) infections are frequent both in the community and in healthcare institutions (nosocomial infections), are associated with high morbidity and mortality rates, and incur high medical costs [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Reduced Susceptibility to Chlorhexidine among Staphylococcus aureus Isolates in Israel: Phenotypic and Genotypic Tolerance

et al. 2021

View full text Add to dashboard Cite

Antiseptic use for body decolonization is the main activity applied to prevent healthcare-associated infections, including those caused by S. aureus. Consequentially, tolerance to several antiseptics such as chlorhexidine gluconate (CHG) has developed. This study aimed to estimate the prevalence of CHG tolerance among S. aureus strains in Israel and to evaluate factors that may affect this tolerance. Furthermore, it tested the associations between phenotypic and genotypic CHG tolerance. S. aureus strains (n = 190) were isolated from clinical samples of patients admitted to various medical institutions in Israel. Phenotypic susceptibility to CHG was assessed by determining minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Genotypic tolerance was detected using real-time PCR for detection of qac A/B genes. MIC for the antibiotic mupirocin was determined using the Etest method. Presence of the Panton–Valentine Leucocidin (pvl) toxin, mecA and mecC genes was detected using an eazyplex® MRSAplus kit (AmplexDiagnostics GmbH, Gars, Germany). CHG tolerance was observed in 13.15% of the isolates. An association between phenotypic and genotypic tolerance to CHG was observed. Phenotypic tolerance to CHG was associated with methicillin resistance but not with mupirocin resistance. Additionally, most of the CHG-tolerant strains were isolated from blood cultures. In conclusion, this work shed light on the prevalence of reduced susceptibility to CHG among S. aureus strains in Israel and on the characteristics of tolerant strains. CHG-tolerant strains were more common than methicillin-resistant ones in samples from invasive infections. Further research should be performed to evaluate risk factors for the development of CHG tolerance.

show abstract

“…Staphylococcus aureus is one of the most common causes for human diseases. This Gram-positive bacterium causes various infections, ranging from skin and soft tissue infections, to pneumonia, meningitis, and sepsis (Tatarkiewicz et al, 2016). S. aureus infections are frequent in both community and health-care institutes, and result in high morbidity and mortality rates and high costs (Purrello et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

“…In 2014, the U.S. Food and Drug administration (USFDA) approved new antimicrobial agents, Dalbavancin and Tedizolid, for treatment of acute bacterial skin and skin-structure infections caused by MRSA (Tatarkiewicz et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

Azrad

Baum

Rokney

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years. We examined whether the spa types affect the susceptibility of the different strains. Methods: We analyzed 275 Methicillin-resistant S. aureus strains recovered from 128 blood and 147 wound samples. For each strain, we performed minimum inhibitory concentration for Tedizolid and Dalbavancin and spa typing. We also performed a non-systematic review of the worldwide literature from the last four years concerning the in vitro activity of Tedizolid and Dalbavancin using the PubMed database; results were restricted by Results: We found one Dalbavancin-resistant isolate (0.36%) and no resistance to Tedizolid. The minimum inhibitory concentration values were dependent in the strain source (wound vs. blood) for both antibiotics. For Dalbavancin, there was also dependence on the spa type. Conclusion: This study indicates Tedizolid and Dalbavancin have potent in vitro activity against the prevalent S. aureus clones in Israel. Further studies should be performed in order to uncover the factors contributing to reduced susceptibility of S. aureus strains to new drugs.

show abstract

New agents approved for treatment of acute staphylococcal skin infections

Cited by 18 publications

References 33 publications

A Peep in to Novel Therapies in Diabetic Foot Ulcer

A Peep in to Novel Therapies in Diabetic Foot Ulcer

Reduced Susceptibility to Chlorhexidine among Staphylococcus aureus Isolates in Israel: Phenotypic and Genotypic Tolerance

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

Contact Info

Product

Resources

About